I do have a quick question just in follow-up to that comment, because we've heard often today already that there are other pieces in order to be able to effectively manufacture vaccines, and that's quite a reasonable claim. As I say, I think many people are not surprised to hear that.
We have the governments of India, South Africa and others coming to the table pursuing an initiative that takes time and resources for them, in order to try to mobilize a global campaign of governments signing on to this waiver to take this issue up repeatedly at the World Trade Organization. Surely, it can't be your position that it will be news to them to find out, once they have broader access to the intellectual property involved, that there are other dimensions to manufacturing a vaccine. I find it very hard to believe that they put the effort into organizing behind this waiver in ignorance of the fact that there are a number of factors that go into the manufacturing of a vaccine, and it'll be a surprise to them, when they get the IP, that the people they've been working with domestically aren't able to produce the vaccine.
I find it insufficient for me to hear of these other factors. As I say, I think reasonable people would expect that there are many things that go into this kind of complex manufacturing process. However, the idea that somehow the proponents of the waiver would be ignorant of that and that they wouldn't have promising leads within their own country, where intellectual property is either the primary barrier or a significant barrier to increasing their production, strikes me as very hard to believe.
I see that we have another witness with their hand up, who just moved on their screen. It might be Ms. Silverman and her colleague from the institute.
Perhaps you'd like to weigh in on that question.